These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 19903782)

  • 21. Expression and prognostic significance of cancer stem cell markers CD24 and CD44 in urothelial bladder cancer xenografts and patients undergoing radical cystectomy.
    Hofner T; Macher-Goeppinger S; Klein C; Schillert A; Eisen C; Wagner S; Rigo-Watermeier T; Baccelli I; Vogel V; Trumpp A; Sprick MR
    Urol Oncol; 2014 Jul; 32(5):678-86. PubMed ID: 24631171
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
    Tzai TS; Tsai YS; Chow NH
    Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
    [TBL] [Abstract][Full Text] [Related]  

  • 23. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer.
    Shariat SF; Tokunaga H; Zhou J; Kim J; Ayala GE; Benedict WF; Lerner SP
    J Clin Oncol; 2004 Mar; 22(6):1014-24. PubMed ID: 14981102
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nomograms provide improved accuracy for predicting survival after radical cystectomy.
    Shariat SF; Karakiewicz PI; Palapattu GS; Amiel GE; Lotan Y; Rogers CG; Vazina A; Bastian PJ; Gupta A; Sagalowsky AI; Schoenberg M; Lerner SP
    Clin Cancer Res; 2006 Nov; 12(22):6663-76. PubMed ID: 17121885
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease.
    Margulis V; Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
    Clin Cancer Res; 2006 Dec; 12(24):7369-73. PubMed ID: 17189409
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder.
    Xylinas E; Robinson BD; Kluth LA; Volkmer BG; Hautmann R; Küfer R; Zerbib M; Kwon E; Thompson RH; Boorjian SA; Shariat SF
    Eur J Surg Oncol; 2014 Jan; 40(1):121-7. PubMed ID: 24140000
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dysregulation of mammalian target of rapamycin pathway in upper tract urothelial carcinoma.
    Munari E; Fujita K; Faraj S; Chaux A; Gonzalez-Roibon N; Hicks J; Meeker A; Nonomura N; Netto GJ
    Hum Pathol; 2013 Dec; 44(12):2668-76. PubMed ID: 24074531
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new prognostic model for cancer-specific survival after radical cystectomy including pretreatment thrombocytosis and standard pathological risk factors.
    Todenhöfer T; Renninger M; Schwentner C; Stenzl A; Gakis G
    BJU Int; 2012 Dec; 110(11 Pt B):E533-40. PubMed ID: 22578156
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survivin expression as a predictive marker for local control in patients with high-risk T1 bladder cancer treated with transurethral resection and radiochemotherapy.
    Weiss C; von Römer F; Capalbo G; Ott OJ; Wittlinger M; Krause SF; Sauer R; Rödel C; Rödel F
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1455-60. PubMed ID: 19231102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insulin-like growth factor-1 receptor overexpression is associated with outcome in invasive urothelial carcinoma of urinary bladder: a retrospective study of patients treated using radical cystectomy.
    Gonzalez-Roibon N; Kim JJ; Faraj SF; Chaux A; Bezerra SM; Munari E; Ellis C; Sharma R; Keizman D; Bivalacqua TJ; Schoenberg M; Eisenberger M; Carducci M; Netto GJ
    Urology; 2014 Jun; 83(6):1444.e1-6. PubMed ID: 24713135
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer.
    Fristrup N; Ulhøi BP; Birkenkamp-Demtröder K; Mansilla F; Sanchez-Carbayo M; Segersten U; Malmström PU; Hartmann A; Palou J; Alvarez-Múgica M; Zieger K; Borre M; Ørntoft TF; Dyrskjøt L
    Am J Pathol; 2012 May; 180(5):1824-34. PubMed ID: 22449953
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of survivin, a novel inhibitor of apoptosis, in superficial transitional cell carcinoma of the bladder.
    Ku JH; Kwak C; Lee HS; Park HK; Lee E; Lee SE
    J Urol; 2004 Feb; 171(2 Pt 1):631-5. PubMed ID: 14713775
    [TBL] [Abstract][Full Text] [Related]  

  • 33. External validation of postoperative nomograms for prediction of all-cause mortality, cancer-specific mortality, and recurrence in patients with urothelial carcinoma of the bladder.
    Nuhn P; May M; Sun M; Fritsche HM; Brookman-May S; Buchner A; Bolenz C; Moritz R; Herrmann E; Burger M; Tilki D; Trojan L; Perrotte P; Haferkamp A; Hohenfellner M; Wieland WF; Müller SC; Karakiewicz PI; Bastian PJ
    Eur Urol; 2012 Jan; 61(1):58-64. PubMed ID: 21840642
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Introduction and first clinical application of a simplified immunohistochemical validation system confirms prognostic impact of KI-67 and CK20 for stage T1 urothelial bladder carcinoma: single-center analysis of eight biomarkers in a series of three hundred six patients.
    Otto W; Denzinger S; Fritsche HM; Burger M; Rößler W; Bertz S; May M; Hartmann A; Hofstädter F; Wieland WF; Eder F
    Clin Genitourin Cancer; 2013 Dec; 11(4):537-44. PubMed ID: 23850551
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low level STK15 amplification in histologically benign urothelium of patients with bladder cancer adversely predicts patient outcome following cystectomy.
    Denzinger S; Stoehr R; Schwarz S; Eichenseher N; Brockhoff G; Obermann EC; Knuechel R; Blaszyk H; Hartmann A; Wild PJ
    Int J Oncol; 2007 Oct; 31(4):793-802. PubMed ID: 17786310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gender-specific outcomes of bladder cancer patients: a stage-specific analysis in a contemporary, homogenous radical cystectomy cohort.
    Soave A; Dahlem R; Hansen J; Weisbach L; Minner S; Engel O; Kluth LA; Chun FK; Shariat SF; Fisch M; Rink M
    Eur J Surg Oncol; 2015 Mar; 41(3):368-77. PubMed ID: 24674298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression and antigenicity of survivin, an inhibitor of apoptosis family member, in bladder cancer: implications for specific immunotherapy.
    Kitamura H; Torigoe T; Honma I; Asanuma H; Nakazawa E; Shimozawa K; Hirohashi Y; Sato E; Sato N; Tsukamoto T
    Urology; 2006 May; 67(5):955-9. PubMed ID: 16635519
    [TBL] [Abstract][Full Text] [Related]  

  • 38. External validation of preoperative and postoperative nomograms for prediction of cancer-specific survival, overall survival and recurrence after robot-assisted radical cystectomy for urothelial carcinoma of the bladder.
    Al-Daghmin A; English S; Kauffman EC; Din R; Khan A; Syed JR; Sztorc J; Mehedint D; Sharif M; Shi Y; Wilding G; Guru KA
    BJU Int; 2014 Aug; 114(2):253-60. PubMed ID: 24119175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of previous or synchronous bladder cancer on oncologic outcomes after radical nephroureterectomy for upper urinary tract urothelial carcinoma.
    Pignot G; Colin P; Zerbib M; Audenet F; Soulié M; Hurel S; Delage F; Irani J; Descazeaud A; Droupy S; Rozet F; Phé V; Ruffion A; Long JA; Crouzet S; Houlgatte A; Bigot P; Guy L; Faïs PO; Rouprêt M;
    Urol Oncol; 2014 Jan; 32(1):23.e1-8. PubMed ID: 23403206
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of smoking and smoking cessation on outcomes in bladder cancer patients treated with radical cystectomy.
    Rink M; Zabor EC; Furberg H; Xylinas E; Ehdaie B; Novara G; Babjuk M; Pycha A; Lotan Y; Trinh QD; Chun FK; Lee RK; Karakiewicz PI; Fisch M; Robinson BD; Scherr DS; Shariat SF
    Eur Urol; 2013 Sep; 64(3):456-64. PubMed ID: 23206854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.